The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Balancing efficacy and safety in lentiviral vector-mediated hematopoietic stem cell gene therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No adverse events associated with vector insertion have been reported to date and, although the lentiviral configuration is very similar to that used in cALD, the striking difference is that an internal cellular promoter sequence (derived from the human PGK gene) was used to direct ubiquitous gene expression.”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [60]
In the citing paper
“In a long-term follow-up study of 29 pediatric patients treated with atidarsagene autotemcel, an approved product in the United States and Europe (Lenmeldy), 26 patients were alive with a median follow-up of 3.16 years (range, 0.64-7.51years), and the majority recovered or experienced stabilization in motor function and displayed normal cognitive development.60”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189
Self-citationHematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Duncan, C. N., Bledsoe, J. R., Grzywacz, B., Beckman, A., Bonner, M., Eichler, F. S., Kühl, J.-S., Harris, M. H., Slauson, S., Colvin, R. A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405541 · Cited by 164
Research works printed but not linked: 12
- Ferrari, 2021, Gene therapy using haematopoietic stem and progenitor cells, Nat. Rev. Genet., 22, 216, 10.1038/s41576-020-00298-5 · DOI
- Ferrari, 2023, Genetic engineering meets hematopoietic stem cell biology for next-generation gene therapy, Cell Stem Cell, 30, 549, 10.1016/j.stem.2023.04.014 · DOI
- Calabria, 2024, Long-term lineage commitment in hematopoietic stem cell gene therapy, Nature, 636, 162, 10.1038/s41586-024-08250-x · DOI
- Masiuk, 2024, Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID), Blood, 144, 10.1182/blood-2024-202543 · DOI
- Cesana, 2012, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations, J. Clin. Invest., 122, 1667, 10.1172/JCI62189 · DOI
- De Ravin, 2022, Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency, Nat. Commun., 13, 3710, 10.1038/s41467-022-31344-x · DOI · Paper page
- Goyal, 2022, Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease, N. Engl. J. Med., 386, 138, 10.1056/NEJMoa2109167 · DOI · Paper page
- Jones, 2021, Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither, Blood, 138, 942, 10.1182/blood.2021011488 · DOI
- Challita, 1995, Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells, J. Virol., 69, 748, 10.1128/jvi.69.2.748-755.1995 · DOI
- Dunbar, 2024, Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy, N. Engl. J. Med., 391, 1358, 10.1056/NEJMe2409399 · DOI
- Reinhardt, 2021, Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency, Blood, 138, 1304, 10.1182/blood.2020010260 · DOI
- Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science (New York, NY), 341, 1233158, 10.1126/science.1233158 · DOI · Paper page
Cited by
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Self-citation
Metadata
- Authors
- Montini, E., Naldini, L., Booth, C., Kohn, D. B., & Aiuti, A.
- ORCID
- Montini, Eugenio
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2025-01
- Volume
- 33
- Issue
- 1
- Pages
- 6-8
- ISSN
- 1525-0016
- Cited by
- 18
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
